0
2022
Car T-cell Therapy Market

CAR T-Cell therapy Market

by Drug type (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Others), by Indication (Lymphoma, Acute Lymphocytic Leukemia, Others), by End user (Hospitals, Cancer Treatment Centers): Global Opportunity Analysis and Industry Forecast, 2022-2031

Report Code: A16971
Jul 2022 | Pages: 315
Tables: 131
Charts: 57
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

CAR T-Cell Therapy Market Research, 2031

The global car t-cell therapy market size was valued at $1.7 billion in 2021, and is projected to reach $6.1 billion by 2031, growing at a CAGR of 13.5% from 2022 to 2031. Chimeric antigen receptor (CAR) T-cell therapy is a new type of cancer treatment, in which   healthcare professionals change to T-cells in the lab and then infuse into the body of cancer patient, so they can find and destroy cancer cells. CAR T-cell therapy is a method of training the immune system to recognize cancerous cells. It is called as gene or cell therapy. CAR T-cell therapy is used to enhance the immune response against cancerous cells.

The COVID-19 pandemic had a negative impact on the CAR T-Cell therapy market because priority is given to COVID-19 patient for treatment. Discovery and development of CAR T-cell therapy medicine slowed down during the pandemic but did not stop. The significant reduction in clinical trials due to strict government guidelines against COVID-19, resists the growth of CAR T-cell therapy market. Decline in people transit, closing of borders, and confinement of the population impacted the supply chains of these life-saving medical products in the CAR T-cell therapy market.

CAR T-Cell therapy Market

Leukemia is a type of cancer, which affects the production and function of blood cells. This causes swollen lymph nodes, recurrent nosebleeds, tiredness, frequent infections, weight loss, bleeding, and bone pain. Lymphoma is a cancer of the lymphatic system, which is part of the body's germ-fighting network. Lymphoma develops in lymphocytes, which are a type of white blood cell. These cells help to fight against infectious diseases in the body and play an essential role in the body’s immune defenses.

The benefits of CAR T-cell therapies over conventional drugs, include the destruction of cancer cells using patients' immune system, early recovery, and shortened treatment time. In addition, CAR T-cell therapy survives for a long time in the body, as they have the ability to recognize and target cancer cells even if the cancer relapses. The CAR T-cell therapy is mainly used for the treatment of lymphoma, acute lymphocytic leukemia, and multiple myeloma blood cancer. Owing to its various advantage over conventional drugs, the CAR T-cell therapy products witness a high adoption rate; which eventually leads to the growth in the CAR T-cell therapy market.

The major factors that drive the CAR T-cell therapy market is surge in demand for ideal therapeutics for treatment of cancer, increase in prevalence of cancer, favorable reimbursement policies in some countries regarding CAR T-cell therapy medicine, and rise in awareness of CAR T-cell therapy medicine. The CAR T-cell therapy market is witnessing a rise, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, which are expected to offer lucrative opportunities for market expansion.

However, the sales of CAR T-cell therapy medicine have witnessed hindrances, owing to lack of skilled professionals for given CAR T-cell therapy in some developing and underdeveloped countries. Higher cost of the therapy also hampers the market growth.   Conversely, rise in awareness and increase in approval of new medicine of CAR T-cell therapy and promising drugs present in pipelines are anticipated to offer remunerative opportunities for the expansion during global CAR T-cell therapy market forecast period.

Rise in prevalence of multiple myeloma cancer and increase in incidences of lymphoma and leukemia lead to high adoption of CAR T-cell therapy product, which propel to market growth. For instance, according to the LEUKEMIA and LYMPHOMA SOCIETY, an estimated 34,920 new cases of myeloma (19,320 males and 15,600 females) were expected to be diagnosed in the U.S. in 2021 and an estimated 138,415 people in the U.S. are living with or in remission from myeloma. According to the LEUKEMIA and LYMPHOMA SOCIETY, in 2021, 61,090 people were expected to be diagnosed with leukemia in the U.S., and an estimated 397,501 people are living with or in remission from leukemia in the U.S.  

The COVID-19 outbreak is anticipated to have a negative impact on the market, as huge number of medical college and hospitals across the globe were restructured to increase the hospital capacity for patients diagnosed with COVID-19. The COVID-19 pandemic had a negative impact on the  market because priority is given to COVID-19 patient for treatment. Discovery and development of CAR T-cell therapy medicine slowed down during the pandemic but did not stop. The significant reduction in clinical trials due to strict government guidelines against COVID-19, resists the growth of CAR T-cell therapy market size. Decline in people transit, closing of borders, and confinement of the population impacted the supply chains of these life-saving medical products in the CAR T-cell therapy market share. Nonessential surgical procedures took a potential backlog and home setting care was preferred, owing to rapidly rising COVID-19 cases, as only elective emergency surgeries were performed.

Therefore, this is anticipated to slowdown in market growth during the ongoing pandemic. However, owing to the introduction of various COVID-19 vaccination, people can readily reach out to hospital and cancer treatment centers, due to which surge in the demand of CAR T-cell therapy is expected in the near future. The demand of CAR T-cell therapy medicine is expected to increase, owing to surge in the R&D activities, rapidly expanding clinical trial activities, and recent commercialization of CAR-T cell therapy. Thus, such development is anticipated to bring stabilization and drive the CAR T-cell therapy market growth.

The CAR T-cell therapy market is segmented into Indication, End user and Drug type.

The CAR T-cell therapy market is segmented on the basis of product type, indication, end user, and region. On the basis of product type, the market is classified into axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel,  and others. By indication, the market is segregated into lymphoma, acute lymphocytic leukemia, and others. Depending on end user, it is fragmented into hospitals and cancer treatment centers.

Region-wise, the market is analyzed across North America (the U.S. and Canada), Europe (Germany, France, UK  and rest of Europe), Asia-Pacific (Japan, China,  and rest of Asia-Pacific), and LAMEA (Latin America and Middle East and Africa)

Segment Review

By drug type, the axicabtagene ciloleucel segment was the highest revenue contributor to the market, owing to increase in adoption of (Yescarta) axicabtagene Ciloleucel medicine for treatment of relapsed or refractory large B-cell lymphoma, relapsed or refractory follicular lymphoma. The brexucabtagene autoleucel segment is expected to witness the highest CAGR during the forecast period, owing to rise in approval of CAR T-cell therapy medicine in different countries for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).  

CAR T-Cell therapy Market
By Drug Type

Your browser does not support the canvas element.

Axicabtagene Ciloleucel segment held a dominant position in 2021 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

On the basis of indication, the lymphoma segment generated maximum revenue in 2021, owing to higher number of approved CAR T-cell therapeutics for treatment of different form of lymphoma with large number of target population. The acute lymphocytic leukemia segment is expected to witness the highest CAGR during the forecast period, owing to increase in awareness of CAR T-cell therapeutics for treatment of acute lymphoblastic leukemia and expected launch of these drug for treatment of acute lymphoblastic leukemia regarding testing of blood cancer.

CAR T-Cell therapy Market
By Indication

Your browser does not support the canvas element.

Lymphoma segment held a dominant position in 2021 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

On the basis of end user, the hospitals segment was the highest revenue contributor to the market in 2021, owing to factors such as well-equipped operation theatre, higher buying power, and rise in patient admission. The cancer treatment centers segment is expected to witness the highest CAGR during the forecast period, owing to availability of a wide range of choice of treatment and increase in the number of cancer centers in some developing nations.

CAR T-Cell therapy Market
By End User

Your browser does not support the canvas element.

Hospitals segment held a dominant position in 2021 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Depending on region, North America generated the highest revenue in 2021 owing to strong presence of key players and availability of approved therapeutics with higher adoption of CAR T cell therapies. Asia-Pacific is expected to witness the highest CAGR during the forecast period owing to rise in awareness regarding CAR T-cell therapy, expected launch of CART drugs, and rise in the number of target population.

CAR T-Cell therapy Market
By Region

2031
North America 
Europe
Asia-Pacific
LAMEA

North America was holding a dominant position in 2021 and would continue to maintain the lead over the analysis period.

Get more information on this report : Request Sample Pages

The key players operating in the CAR T-cell therapy industry are Autolus, Bluebird Bio-Inc., Bristol-Myers Squibb, Caribou Biosciences Inc., Cartesian Therapeutics, Celgene Corporation, Cellectis, Celyad, Gilead Sciences, Inc. (Kite Pharma Inc.), Intellia Therapeutics, Juno Therapeutics, Merck & Co. Inc., Miltenyi Biotech, Novartis AG, Pfizer Inc., and Sorrento Therapeutics, Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the car t-cell therapy market analysis from 2021 to 2031 to identify the prevailing car t-cell therapy market opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the car t-cell therapy market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global car t-cell therapy market trends, key players, market segments, application areas, and market growth strategies.

CAR T-Cell therapy Market Report Highlights

Aspects Details
Market Size By 2031 USD 6.1 billion
Growth Rate CAGR of 13.5%
Forecast period 2021 - 2031
Report Pages 315
By Drug type
  • Axicabtagene Ciloleucel
  • Tisagenlecleucel
  • Brexucabtagene Autoleucel
  • Others
By Indication
  • Lymphoma
  • Acute Lymphocytic Leukemia
  • Others
By End user
  • Hospitals
  • Cancer Treatment Centers
By Region
  • North America  (U.S., Canada)
  • Europe  (Germany, France, U.K., Rest of Europe)
  • Asia-Pacific  (Japan, China, Rest of Asia-Pacific)
  • LAMEA  (Latin America, Middle East And Africa)
Key Market Players Celyad Oncology, Gilead Sciences, Inc. (Kite Pharma Inc.), Miltenyi Biotech, Bluebird Bio, Inc., Intellia Therapeutics, Juno Therapeutics, Inc., Novartis AG, Caribou Biosciences, Inc., Pfizer, Inc., Bristol-Myers Squibb, Cellectis, Autolus Therapeutics, Sorrento Therapeutics, Inc., Merck & Co., Inc., Celgene Corporation, Cartesian Therapeutics, Inc.

Analyst Review

CAR T-cell therapy medicines help in treatment of lymphoma, acute lymphocytic leukemia, and multiple myeloma blood cancer. CAR T-cell therapy survives for a long time in the body, as it has the ability to recognize and target cancer cells even if the cancer relapses.

CAR T-cell therapy is gaining high traction in the market, owing to increase in prevalence of cancer, rise in R&D investments in drug discovery & development, and increase in awareness regarding CAR T-cell therapy & diagnosis of cancer. Rapidly expanding clinical trial activities, recent commercialization of CAR-T-cell therapy, and key players in the market are focusing on adopting strategies to increase accessibility and utilization of CAR T-cell therapy products in developing economies, which are expected to fuel the market growth during the forecast period. However, complications and side-effects associated with CAR-T-cell therapy and higher cost of CAR-T-cell therapy hinder the growth of the market.

North America is expected to witness the highest growth, in terms of revenue, owing to increase in cases of cancer, robust healthcare infrastructure, presence of key players, and rise in healthcare expenditure. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in geriatric population, unmet medical demands, initiatives by government & non-governmental organizations (NGOs) to promote awareness regarding CAR T-cell therapy, and increase in public–private investments in the healthcare sector.

 
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report description

    • 1.2. Key market segments

    • 1.3. Key benefits to the stakeholders

    • 1.4. Research Methodology

      • 1.4.1. Primary research

      • 1.4.2. Secondary research

      • 1.4.3. Analyst tools and models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET OVERVIEW

    • 3.1. Market definition and scope

    • 3.2. Key findings

      • 3.2.1. Top impacting factors

      • 3.2.2. Top investment pockets

    • 3.3. Porter’s five forces analysis

      • 3.3.1. Low bargaining power of suppliers

      • 3.3.2. Low threat of new entrants

      • 3.3.3. Low threat of substitutes

      • 3.3.4. Low intensity of rivalry

      • 3.3.5. Low bargaining power of buyers

    • 3.4. Market dynamics

      • 3.4.1. Drivers

        • 3.4.1.1. Surge in prevalence of cancer
        • 3.4.1.2. Rise in awareness regarding CAR T-cell therapy
        • 3.4.1.3. Increase in demand of ideal therapeutics for treatment of cancer

      • 3.4.2. Restraints

        • 3.4.2.1. High cost of CAR T-cell therapies
        • 3.4.2.2. Strict government regulation for approval of drugs

      • 3.4.3. Opportunities

        • 3.4.3.1. Increase in R&D activities to develop CAR T-cell therapeutics

    • 3.5. COVID-19 Impact Analysis on the market

  • CHAPTER 4: CAR T-CELL THERAPY MARKET, BY DRUG TYPE

    • 4.1. Overview

      • 4.1.1. Market size and forecast

    • 4.2. Axicabtagene Ciloleucel

      • 4.2.1. Key market trends, growth factors and opportunities

      • 4.2.2. Market size and forecast, by region

      • 4.2.3. Market share analysis by country

    • 4.3. Tisagenlecleucel

      • 4.3.1. Key market trends, growth factors and opportunities

      • 4.3.2. Market size and forecast, by region

      • 4.3.3. Market share analysis by country

    • 4.4. Brexucabtagene Autoleucel

      • 4.4.1. Key market trends, growth factors and opportunities

      • 4.4.2. Market size and forecast, by region

      • 4.4.3. Market share analysis by country

    • 4.5. Others

      • 4.5.1. Key market trends, growth factors and opportunities

      • 4.5.2. Market size and forecast, by region

      • 4.5.3. Market share analysis by country

  • CHAPTER 5: CAR T-CELL THERAPY MARKET, BY INDICATION

    • 5.1. Overview

      • 5.1.1. Market size and forecast

    • 5.2. Lymphoma

      • 5.2.1. Key market trends, growth factors and opportunities

      • 5.2.2. Market size and forecast, by region

      • 5.2.3. Market share analysis by country

    • 5.3. Acute Lymphocytic Leukemia

      • 5.3.1. Key market trends, growth factors and opportunities

      • 5.3.2. Market size and forecast, by region

      • 5.3.3. Market share analysis by country

    • 5.4. Others

      • 5.4.1. Key market trends, growth factors and opportunities

      • 5.4.2. Market size and forecast, by region

      • 5.4.3. Market share analysis by country

  • CHAPTER 6: CAR T-CELL THERAPY MARKET, BY END USER

    • 6.1. Overview

      • 6.1.1. Market size and forecast

    • 6.2. Hospitals

      • 6.2.1. Key market trends, growth factors and opportunities

      • 6.2.2. Market size and forecast, by region

      • 6.2.3. Market share analysis by country

    • 6.3. Cancer Treatment Centers

      • 6.3.1. Key market trends, growth factors and opportunities

      • 6.3.2. Market size and forecast, by region

      • 6.3.3. Market share analysis by country

  • CHAPTER 7: CAR T-CELL THERAPY MARKET, BY REGION

    • 7.1. Overview

      • 7.1.1. Market size and forecast By Region

    • 7.2. North America

      • 7.2.1. Key trends and opportunities

      • 7.2.2. Market size and forecast, by Drug type

      • 7.2.3. Market size and forecast, by Indication

      • 7.2.4. Market size and forecast, by End user

      • 7.2.5. Market size and forecast, by country

        • 7.2.5.1. U.S.
          • 7.2.5.1.1. Key market trends, growth factors and opportunities
          • 7.2.5.1.2. Market size and forecast, by Drug type
          • 7.2.5.1.3. Market size and forecast, by Indication
          • 7.2.5.1.4. Market size and forecast, by End user
        • 7.2.5.2. Canada
          • 7.2.5.2.1. Key market trends, growth factors and opportunities
          • 7.2.5.2.2. Market size and forecast, by Drug type
          • 7.2.5.2.3. Market size and forecast, by Indication
          • 7.2.5.2.4. Market size and forecast, by End user
    • 7.3. Europe

      • 7.3.1. Key trends and opportunities

      • 7.3.2. Market size and forecast, by Drug type

      • 7.3.3. Market size and forecast, by Indication

      • 7.3.4. Market size and forecast, by End user

      • 7.3.5. Market size and forecast, by country

        • 7.3.5.1. Germany
          • 7.3.5.1.1. Key market trends, growth factors and opportunities
          • 7.3.5.1.2. Market size and forecast, by Drug type
          • 7.3.5.1.3. Market size and forecast, by Indication
          • 7.3.5.1.4. Market size and forecast, by End user
        • 7.3.5.2. France
          • 7.3.5.2.1. Key market trends, growth factors and opportunities
          • 7.3.5.2.2. Market size and forecast, by Drug type
          • 7.3.5.2.3. Market size and forecast, by Indication
          • 7.3.5.2.4. Market size and forecast, by End user
        • 7.3.5.3. U.K.
          • 7.3.5.3.1. Key market trends, growth factors and opportunities
          • 7.3.5.3.2. Market size and forecast, by Drug type
          • 7.3.5.3.3. Market size and forecast, by Indication
          • 7.3.5.3.4. Market size and forecast, by End user
        • 7.3.5.4. Rest of Europe
          • 7.3.5.4.1. Key market trends, growth factors and opportunities
          • 7.3.5.4.2. Market size and forecast, by Drug type
          • 7.3.5.4.3. Market size and forecast, by Indication
          • 7.3.5.4.4. Market size and forecast, by End user
    • 7.4. Asia-Pacific

      • 7.4.1. Key trends and opportunities

      • 7.4.2. Market size and forecast, by Drug type

      • 7.4.3. Market size and forecast, by Indication

      • 7.4.4. Market size and forecast, by End user

      • 7.4.5. Market size and forecast, by country

        • 7.4.5.1. Japan
          • 7.4.5.1.1. Key market trends, growth factors and opportunities
          • 7.4.5.1.2. Market size and forecast, by Drug type
          • 7.4.5.1.3. Market size and forecast, by Indication
          • 7.4.5.1.4. Market size and forecast, by End user
        • 7.4.5.2. China
          • 7.4.5.2.1. Key market trends, growth factors and opportunities
          • 7.4.5.2.2. Market size and forecast, by Drug type
          • 7.4.5.2.3. Market size and forecast, by Indication
          • 7.4.5.2.4. Market size and forecast, by End user
        • 7.4.5.3. Rest of Asia-Pacific
          • 7.4.5.3.1. Key market trends, growth factors and opportunities
          • 7.4.5.3.2. Market size and forecast, by Drug type
          • 7.4.5.3.3. Market size and forecast, by Indication
          • 7.4.5.3.4. Market size and forecast, by End user
    • 7.5. LAMEA

      • 7.5.1. Key trends and opportunities

      • 7.5.2. Market size and forecast, by Drug type

      • 7.5.3. Market size and forecast, by Indication

      • 7.5.4. Market size and forecast, by End user

      • 7.5.5. Market size and forecast, by country

        • 7.5.5.1. Latin America
          • 7.5.5.1.1. Key market trends, growth factors and opportunities
          • 7.5.5.1.2. Market size and forecast, by Drug type
          • 7.5.5.1.3. Market size and forecast, by Indication
          • 7.5.5.1.4. Market size and forecast, by End user
        • 7.5.5.2. Middle East And Africa
          • 7.5.5.2.1. Key market trends, growth factors and opportunities
          • 7.5.5.2.2. Market size and forecast, by Drug type
          • 7.5.5.2.3. Market size and forecast, by Indication
          • 7.5.5.2.4. Market size and forecast, by End user
  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top winning strategies

    • 8.3. Product Mapping of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top player positioning, 2021

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Autolus Therapeutics

      • 9.1.1. Company overview

      • 9.1.2. Key Executives

      • 9.1.3. Company snapshot

      • 9.1.4. Operating business segments

      • 9.1.5. Product portfolio

    • 9.2. Bluebird Bio, Inc.

      • 9.2.1. Company overview

      • 9.2.2. Key Executives

      • 9.2.3. Company snapshot

      • 9.2.4. Operating business segments

      • 9.2.5. Product portfolio

      • 9.2.6. Business performance

      • 9.2.7. Key strategic moves and developments

    • 9.3. Bristol-Myers Squibb

      • 9.3.1. Company overview

      • 9.3.2. Key Executives

      • 9.3.3. Company snapshot

      • 9.3.4. Operating business segments

      • 9.3.5. Product portfolio

      • 9.3.6. Business performance

      • 9.3.7. Key strategic moves and developments

    • 9.4. Caribou Biosciences, Inc.

      • 9.4.1. Company overview

      • 9.4.2. Key Executives

      • 9.4.3. Company snapshot

      • 9.4.4. Operating business segments

      • 9.4.5. Product portfolio

    • 9.5. Cartesian Therapeutics, Inc.

      • 9.5.1. Company overview

      • 9.5.2. Key Executives

      • 9.5.3. Company snapshot

      • 9.5.4. Operating business segments

      • 9.5.5. Product portfolio

    • 9.6. Celgene Corporation

      • 9.6.1. Company overview

      • 9.6.2. Key Executives

      • 9.6.3. Company snapshot

      • 9.6.4. Operating business segments

      • 9.6.5. Product portfolio

    • 9.7. Cellectis

      • 9.7.1. Company overview

      • 9.7.2. Key Executives

      • 9.7.3. Company snapshot

      • 9.7.4. Operating business segments

      • 9.7.5. Product portfolio

      • 9.7.6. Business performance

      • 9.7.7. Key strategic moves and developments

    • 9.8. Celyad Oncology

      • 9.8.1. Company overview

      • 9.8.2. Key Executives

      • 9.8.3. Company snapshot

      • 9.8.4. Operating business segments

      • 9.8.5. Product portfolio

      • 9.8.6. Key strategic moves and developments

    • 9.9. Gilead Sciences, Inc. (Kite Pharma Inc.)

      • 9.9.1. Company overview

      • 9.9.2. Key Executives

      • 9.9.3. Company snapshot

      • 9.9.4. Operating business segments

      • 9.9.5. Product portfolio

      • 9.9.6. Business performance

      • 9.9.7. Key strategic moves and developments

    • 9.10. Intellia Therapeutics

      • 9.10.1. Company overview

      • 9.10.2. Key Executives

      • 9.10.3. Company snapshot

      • 9.10.4. Operating business segments

      • 9.10.5. Product portfolio

    • 9.11. Juno Therapeutics, Inc.

      • 9.11.1. Company overview

      • 9.11.2. Key Executives

      • 9.11.3. Company snapshot

      • 9.11.4. Operating business segments

      • 9.11.5. Product portfolio

    • 9.12. Merck & Co., Inc.

      • 9.12.1. Company overview

      • 9.12.2. Key Executives

      • 9.12.3. Company snapshot

      • 9.12.4. Operating business segments

      • 9.12.5. Product portfolio

      • 9.12.6. Business performance

    • 9.13. Miltenyi Biotech

      • 9.13.1. Company overview

      • 9.13.2. Key Executives

      • 9.13.3. Company snapshot

      • 9.13.4. Operating business segments

      • 9.13.5. Product portfolio

    • 9.14. Novartis AG

      • 9.14.1. Company overview

      • 9.14.2. Key Executives

      • 9.14.3. Company snapshot

      • 9.14.4. Operating business segments

      • 9.14.5. Product portfolio

      • 9.14.6. Business performance

    • 9.15. Pfizer, Inc.

      • 9.15.1. Company overview

      • 9.15.2. Key Executives

      • 9.15.3. Company snapshot

      • 9.15.4. Operating business segments

      • 9.15.5. Product portfolio

      • 9.15.6. Business performance

    • 9.16. Sorrento Therapeutics, Inc.

      • 9.16.1. Company overview

      • 9.16.2. Key Executives

      • 9.16.3. Company snapshot

      • 9.16.4. Operating business segments

      • 9.16.5. Product portfolio

      • 9.16.6. Business performance

  • LIST OF TABLES

  • TABLE 01. GLOBAL CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 02. CAR T-CELL THERAPY MARKET FOR AXICABTAGENE CILOLEUCEL, BY REGION, 2021-2031 ($MILLION)
    TABLE 03. CAR T-CELL THERAPY MARKET FOR TISAGENLECLEUCEL, BY REGION, 2021-2031 ($MILLION)
    TABLE 04. CAR T-CELL THERAPY MARKET FOR BREXUCABTAGENE AUTOLEUCEL, BY REGION, 2021-2031 ($MILLION)
    TABLE 05. CAR T-CELL THERAPY MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
    TABLE 06. GLOBAL CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 07. CAR T-CELL THERAPY MARKET FOR LYMPHOMA, BY REGION, 2021-2031 ($MILLION)
    TABLE 08. CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2021-2031 ($MILLION)
    TABLE 09. CAR T-CELL THERAPY MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
    TABLE 10. GLOBAL CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 11. CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
    TABLE 12. CAR T-CELL THERAPY MARKET FOR CANCER TREATMENT CENTERS, BY REGION, 2021-2031 ($MILLION)
    TABLE 13. CAR T-CELL THERAPY MARKET, BY REGION, 2021-2031 ($MILLION)
    TABLE 14. NORTH AMERICA CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 15. NORTH AMERICA CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 16. NORTH AMERICA CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 17. NORTH AMERICA CAR T-CELL THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 18. U.S. CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 19. U.S. CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 20. U.S. CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 21. CANADA CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 22. CANADA CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 23. CANADA CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 24. EUROPE CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 25. EUROPE CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 26. EUROPE CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 27. EUROPE CAR T-CELL THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 28. GERMANY CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 29. GERMANY CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 30. GERMANY CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 31. FRANCE CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 32. FRANCE CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 33. FRANCE CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 34. U.K. CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 35. U.K. CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 36. U.K. CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 37. REST OF EUROPE CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 38. REST OF EUROPE CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 39. REST OF EUROPE CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 40. ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 41. ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 42. ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 43. ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 44. JAPAN CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 45. JAPAN CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 46. JAPAN CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 47. CHINA CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 48. CHINA CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 49. CHINA CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 50. REST OF ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 51. REST OF ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 52. REST OF ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 53. LAMEA CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 54. LAMEA CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 55. LAMEA CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 56. LAMEA CAR T-CELL THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 57. LATIN AMERICA CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 58. LATIN AMERICA CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 59. LATIN AMERICA CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 60. MIDDLE EAST AND AFRICA CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 61. MIDDLE EAST AND AFRICA CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 62. MIDDLE EAST AND AFRICA CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
    TABLE 63. AUTOLUS THERAPEUTICS: KEY EXECUTIVES
    TABLE 64. AUTOLUS THERAPEUTICS: COMPANY SNAPSHOT
    TABLE 65. AUTOLUS THERAPEUTICS: PRODUCT SEGMENTS
    TABLE 66. AUTOLUS THERAPEUTICS: PRODUCT PORTFOLIO
    TABLE 67. BLUEBIRD BIO, INC.: KEY EXECUTIVES
    TABLE 68. BLUEBIRD BIO, INC.: COMPANY SNAPSHOT
    TABLE 69. BLUEBIRD BIO, INC.: SERVICE SEGMENTS
    TABLE 70. BLUEBIRD BIO, INC.: PRODUCT PORTFOLIO
    TABLE 71. BLUEBIRD BIO, INC.: KEY STRATERGIES
    TABLE 72. BRISTOL-MYERS SQUIBB: KEY EXECUTIVES
    TABLE 73. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
    TABLE 74. BRISTOL-MYERS SQUIBB: PRODUCT SEGMENTS
    TABLE 75. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
    TABLE 76. BRISTOL-MYERS SQUIBB: KEY STRATERGIES
    TABLE 77. CARIBOU BIOSCIENCES, INC.: KEY EXECUTIVES
    TABLE 78. CARIBOU BIOSCIENCES, INC.: COMPANY SNAPSHOT
    TABLE 79. CARIBOU BIOSCIENCES, INC.: PRODUCT SEGMENTS
    TABLE 80. CARIBOU BIOSCIENCES, INC.: PRODUCT PORTFOLIO
    TABLE 81. CARTESIAN THERAPEUTICS, INC.: KEY EXECUTIVES
    TABLE 82. CARTESIAN THERAPEUTICS, INC.: COMPANY SNAPSHOT
    TABLE 83. CARTESIAN THERAPEUTICS, INC.: PRODUCT SEGMENTS
    TABLE 84. CARTESIAN THERAPEUTICS, INC.: PRODUCT PORTFOLIO
    TABLE 85. CELGENE CORPORATION: KEY EXECUTIVES
    TABLE 86. CELGENE CORPORATION: COMPANY SNAPSHOT
    TABLE 87. CELGENE CORPORATION: PRODUCT SEGMENTS
    TABLE 88. CELGENE CORPORATION: PRODUCT PORTFOLIO
    TABLE 89. CELLECTIS: KEY EXECUTIVES
    TABLE 90. CELLECTIS: COMPANY SNAPSHOT
    TABLE 91. CELLECTIS: PRODUCT SEGMENTS
    TABLE 92. CELLECTIS: PRODUCT PORTFOLIO
    TABLE 93. CELLECTIS: KEY STRATERGIES
    TABLE 94. CELYAD ONCOLOGY: KEY EXECUTIVES
    TABLE 95. CELYAD ONCOLOGY: COMPANY SNAPSHOT
    TABLE 96. CELYAD ONCOLOGY: PRODUCT SEGMENTS
    TABLE 97. CELYAD ONCOLOGY: PRODUCT PORTFOLIO
    TABLE 98. CELYAD ONCOLOGY: KEY STRATERGIES
    TABLE 99. GILEAD SCIENCES, INC. (KITE PHARMA INC.): KEY EXECUTIVES
    TABLE 100. GILEAD SCIENCES, INC. (KITE PHARMA INC.): COMPANY SNAPSHOT
    TABLE 101. GILEAD SCIENCES, INC. (KITE PHARMA INC.): PRODUCT SEGMENTS
    TABLE 102. GILEAD SCIENCES, INC. (KITE PHARMA INC.): PRODUCT PORTFOLIO
    TABLE 103. GILEAD SCIENCES, INC. (KITE PHARMA INC.): KEY STRATERGIES
    TABLE 104. INTELLIA THERAPEUTICS: KEY EXECUTIVES
    TABLE 105. INTELLIA THERAPEUTICS: COMPANY SNAPSHOT
    TABLE 106. INTELLIA THERAPEUTICS: PRODUCT SEGMENTS
    TABLE 107. INTELLIA THERAPEUTICS: PRODUCT PORTFOLIO
    TABLE 108. JUNO THERAPEUTICS, INC.: KEY EXECUTIVES
    TABLE 109. JUNO THERAPEUTICS, INC.: COMPANY SNAPSHOT
    TABLE 110. JUNO THERAPEUTICS, INC.: SERVICE SEGMENTS
    TABLE 111. JUNO THERAPEUTICS, INC.: PRODUCT PORTFOLIO
    TABLE 112. MERCK & CO., INC.: KEY EXECUTIVES
    TABLE 113. MERCK & CO., INC.: COMPANY SNAPSHOT
    TABLE 114. MERCK & CO., INC.: PRODUCT SEGMENTS
    TABLE 115. MERCK & CO., INC.: PRODUCT PORTFOLIO
    TABLE 116. MILTENYI BIOTECH: KEY EXECUTIVES
    TABLE 117. MILTENYI BIOTECH: COMPANY SNAPSHOT
    TABLE 118. MILTENYI BIOTECH: PRODUCT SEGMENTS
    TABLE 119. MILTENYI BIOTECH: PRODUCT PORTFOLIO
    TABLE 120. NOVARTIS AG: KEY EXECUTIVES
    TABLE 121. NOVARTIS AG: COMPANY SNAPSHOT
    TABLE 122. NOVARTIS AG: PRODUCT SEGMENTS
    TABLE 123. NOVARTIS AG: PRODUCT PORTFOLIO
    TABLE 124. PFIZER, INC.: KEY EXECUTIVES
    TABLE 125. PFIZER, INC.: COMPANY SNAPSHOT
    TABLE 126. PFIZER, INC.: PRODUCT SEGMENTS
    TABLE 127. PFIZER, INC.: PRODUCT PORTFOLIO
    TABLE 128. SORRENTO THERAPEUTICS, INC.: KEY EXECUTIVES
    TABLE 129. SORRENTO THERAPEUTICS, INC.: COMPANY SNAPSHOT
    TABLE 130. SORRENTO THERAPEUTICS, INC.: PRODUCT SEGMENTS
    TABLE 131. SORRENTO THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • LIST OF FIGURES

  • FIGURE 1.CAR T-CELL THERAPY MARKET SEGMENTATION
    FIGURE 2.CAR T-CELL THERAPY MARKET,2021-2031
    FIGURE 3.CAR T-CELL THERAPY MARKET,2021-2031
    FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
    FIGURE 5.PORTER FIVE-1
    FIGURE 6.PORTER FIVE-2
    FIGURE 7.PORTER FIVE-3
    FIGURE 8.PORTER FIVE-4
    FIGURE 9.PORTER FIVE-5
    FIGURE 10.TOP PLAYER POSITIONING
    FIGURE 11.CAR T-CELL THERAPY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
    FIGURE 12.CAR T-CELL THERAPY MARKET,BY DRUG TYPE,2021(%)
    FIGURE 13.COMPARATIVE SHARE ANALYSIS OF AXICABTAGENE CILOLEUCEL CAR T-CELL THERAPY MARKET,2021-2031(%)
    FIGURE 14.COMPARATIVE SHARE ANALYSIS OF TISAGENLECLEUCEL CAR T-CELL THERAPY MARKET,2021-2031(%)
    FIGURE 15.COMPARATIVE SHARE ANALYSIS OF BREXUCABTAGENE AUTOLEUCEL CAR T-CELL THERAPY MARKET,2021-2031(%)
    FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OTHERS CAR T-CELL THERAPY MARKET,2021-2031(%)
    FIGURE 17.CAR T-CELL THERAPY MARKET,BY INDICATION,2021(%)
    FIGURE 18.COMPARATIVE SHARE ANALYSIS OF LYMPHOMA CAR T-CELL THERAPY MARKET,2021-2031(%)
    FIGURE 19.COMPARATIVE SHARE ANALYSIS OF ACUTE LYMPHOCYTIC LEUKEMIA CAR T-CELL THERAPY MARKET,2021-2031(%)
    FIGURE 20.COMPARATIVE SHARE ANALYSIS OF OTHERS CAR T-CELL THERAPY MARKET,2021-2031(%)
    FIGURE 21.CAR T-CELL THERAPY MARKET,BY END USER,2021(%)
    FIGURE 22.COMPARATIVE SHARE ANALYSIS OF HOSPITALS CAR T-CELL THERAPY MARKET,2021-2031(%)
    FIGURE 23.COMPARATIVE SHARE ANALYSIS OF CANCER TREATMENT CENTERS CAR T-CELL THERAPY MARKET,2021-2031(%)
    FIGURE 24.CAR T-CELL THERAPY MARKET BY REGION,2021
    FIGURE 25.U.S. CAR T-CELL THERAPY MARKET,2021-2031($MILLION)
    FIGURE 26.CANADA CAR T-CELL THERAPY MARKET,2021-2031($MILLION)
    FIGURE 27.GERMANY CAR T-CELL THERAPY MARKET,2021-2031($MILLION)
    FIGURE 28.FRANCE CAR T-CELL THERAPY MARKET,2021-2031($MILLION)
    FIGURE 29.U.K. CAR T-CELL THERAPY MARKET,2021-2031($MILLION)
    FIGURE 30.REST OF EUROPE CAR T-CELL THERAPY MARKET,2021-2031($MILLION)
    FIGURE 31.JAPAN CAR T-CELL THERAPY MARKET,2021-2031($MILLION)
    FIGURE 32.CHINA CAR T-CELL THERAPY MARKET,2021-2031($MILLION)
    FIGURE 33.REST OF ASIA-PACIFIC CAR T-CELL THERAPY MARKET,2021-2031($MILLION)
    FIGURE 34.LATIN AMERICA CAR T-CELL THERAPY MARKET,2021-2031($MILLION)
    FIGURE 35.MIDDLE EAST AND AFRICA CAR T-CELL THERAPY MARKET,2021-2031($MILLION)
    FIGURE 36. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 37. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 38. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 39.PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 40.COMPETITIVE DASHBOARD
    FIGURE 41.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
    FIGURE 42.AUTOLUS THERAPEUTICS.: NET SALES ,($MILLION)
    FIGURE 43.BLUEBIRD BIO, INC..: NET SALES ,($MILLION)
    FIGURE 44.BRISTOL-MYERS SQUIBB.: NET SALES ,($MILLION)
    FIGURE 45.CARIBOU BIOSCIENCES, INC..: NET SALES ,($MILLION)
    FIGURE 46.CARTESIAN THERAPEUTICS, INC..: NET SALES ,($MILLION)
    FIGURE 47.CELGENE CORPORATION.: NET SALES ,($MILLION)
    FIGURE 48.CELLECTIS.: NET SALES ,($MILLION)
    FIGURE 49.CELYAD ONCOLOGY.: NET SALES ,($MILLION)
    FIGURE 50.GILEAD SCIENCES, INC. (KITE PHARMA INC.).: NET SALES ,($MILLION)
    FIGURE 51.INTELLIA THERAPEUTICS.: NET SALES ,($MILLION)
    FIGURE 52.JUNO THERAPEUTICS, INC..: NET SALES ,($MILLION)
    FIGURE 53.MERCK & CO., INC..: NET SALES ,($MILLION)
    FIGURE 54.MILTENYI BIOTECH.: NET SALES ,($MILLION)
    FIGURE 55.NOVARTIS AG.: NET SALES ,($MILLION)
    FIGURE 56.PFIZER, INC..: NET SALES ,($MILLION)
    FIGURE 57.SORRENTO THERAPEUTICS, INC..: NET SALES ,($MILLION)

 
 

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The upcoming trends of CAR T-Cell therapy Market includes approved CAR T-cell therapeutics for treatment of different form of lymphoma with large number of target population.

A. The leading application of CAR T-Cell therapy Market are lymphoma and immunotherapy.

A. North America is the largest regional market for CAR T-Cell therapy.

A. CAR T-Cell therapy is estimated to reach $ 6,093.10 million by 2031, growing at a CAGR of 13.5% from 2022 to 2031.

A. The key players operating in the CAR T-cell therapy market are Autolus, Bluebird Bio-Inc., Bristol-Myers Squibb, Caribou Biosciences Inc., Cartesian Therapeutics, Celgene Corporation, Cellectis, Celyad, Gilead Sciences, Inc. (Kite Pharma Inc.), Intellia Therapeutics, Juno Therapeutics, Merck & Co. Inc., Miltenyi Biotech, Novartis AG, Pfizer Inc., and Sorrento Therapeutics, Inc.

A. The base year is 2021 in CAR T-Cell therapy market.

A. The forecast period for CAR T-Cell therapy market is 2022 to 2031.

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Sample
RELATED TAGS

Purchase Full Report of
Car T-cell Therapy Market

Start reading instantly.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,570
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Jul 2023 - Jul 2024)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jul 2023 - Jul 2024)
  • Single User
  • $5,730
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jul 2023 - Jul 2024)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jul 2023 - Jul 2024)
  • Enterprise
    License/PDF

  • $9,600
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jul 2023 - Jul 2024)
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers